Studying a rare immune cell subtype with low circulating abundance? One of our biotech customers developing curative therapies for a chronic viral infection switched to apheresis-collected leukopaks to reliably obtain higher yields of infected cells.
Challenge Standard blood draws from patients with chronic viral infections often fail to yield sufficient quantities of rare immune cells harboring viral genetic material.
Solution Sanguine recruited 20 apheresis donors with confirmed chronic viral infection from its 70,000+ member Patient Community. Each collection safely yields ~100X more PBMCs in one sitting than venipuncture.
Outcome Leukopaks can more confidently provide adequate rare cells for isolation and analysis, whereas standard blood draws risk yielding inadequate material.